Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam
Dravet syndrome (DS) is a rare, severe childhood epilepsy syndrome that imposes a substantial burden on patients and their caregivers. This study evaluated health-care utilization over a 2-year period in patients with DS at an outpatient clinic of a German epilepsy center. Data on the course of epil...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
13 April 2014
|
| In: |
Epilepsy & behavior
Year: 2014, Jahrgang: 34, Pages: 86-91 |
| ISSN: | 1525-5069 |
| DOI: | 10.1016/j.yebeh.2014.03.014 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.yebeh.2014.03.014 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S152550501400095X 
|
| Verfasserangaben: | Adam Strzelczyk, Susanne Schubert-Bast, Jens P. Reese, Felix Rosenow, Ulrich Stephani, Rainer Boor |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1728845440 | ||
| 003 | DE-627 | ||
| 005 | 20230426091339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200903s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.yebeh.2014.03.014 |2 doi | |
| 035 | |a (DE-627)1728845440 | ||
| 035 | |a (DE-599)KXP1728845440 | ||
| 035 | |a (OCoLC)1341358485 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Strzelczyk, Adam |d 1978- |e VerfasserIn |0 (DE-588)134251229 |0 (DE-627)565617621 |0 (DE-576)278643280 |4 aut | |
| 245 | 1 | 0 | |a Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam |c Adam Strzelczyk, Susanne Schubert-Bast, Jens P. Reese, Felix Rosenow, Ulrich Stephani, Rainer Boor |
| 264 | 1 | |c 13 April 2014 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.09.2020 | ||
| 520 | |a Dravet syndrome (DS) is a rare, severe childhood epilepsy syndrome that imposes a substantial burden on patients and their caregivers. This study evaluated health-care utilization over a 2-year period in patients with DS at an outpatient clinic of a German epilepsy center. Data on the course of epilepsy, anticonvulsant treatment, and direct costs were recorded using the electronic seizure diary Epivista® and patients' files. We enrolled 13 patients with DS (6 females, mean age: 12.3±7.5years) between 2007 and 2010 and evaluated them during a 1-year baseline. All patients had drug-resistant epilepsy and their seizures failed to improve with a mean number of 6.7±3.4 anticonvulsants. They had an overall mean seizure frequency of 102.1seizures per year (median: 31, range: 3-538) with 43.2GTCSs per year (median: 14, range: 0-228). We estimated the annual total direct costs at €6506±3974 (range: €1174-11,783) per patient with hospitalization (68.9% of total direct costs) as the major cost factor ahead of costs for anticonvulsants (24.0%). For the 1-year follow-up period, less severely affected patients were continued on conventional anticonvulsants (n=4) or switched to adjunctive treatment with stiripentol and clobazam (n=9). In the latter group, six patients (67%) were long-term responders, with between 25% and 100% seizure reduction with respect to either GTCSs or the overall seizure frequency. This reduction in seizure frequency was associated with a shift in the distribution of cost components towards higher medication costs and decreased hospitalization costs. The total direct costs increased by 42.7%, mainly due to the newly introduced stiripentol, with an annual cost of €6610. This study showed that direct costs of patients with DS were above the average European costs of drug-resistant epilepsy in children. Treatment with new anticonvulsants resulted in reduction of seizures and inpatient admissions. | ||
| 650 | 4 | |a Cost | |
| 650 | 4 | |a Dravet syndrome | |
| 650 | 4 | |a Economic burden | |
| 650 | 4 | |a Epilepsy | |
| 650 | 4 | |a Pharmacoeconomic study | |
| 650 | 4 | |a Stiripentol | |
| 700 | 1 | |a Schubert-Bast, Susanne |d 1971- |e VerfasserIn |0 (DE-588)12459347X |0 (DE-627)363431675 |0 (DE-576)294248722 |4 aut | |
| 700 | 1 | |a Reese, Jens P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rosenow, Felix |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stephani, Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boor, Rainer |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Epilepsy & behavior |d New York, NY [u.a.] : Elsevier, 2000 |g 34(2014), Seite 86-91 |h Online-Ressource |w (DE-627)320590313 |w (DE-600)2018844-4 |w (DE-576)261570382 |x 1525-5069 |7 nnas |a Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam |
| 773 | 1 | 8 | |g volume:34 |g year:2014 |g pages:86-91 |g extent:6 |a Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.yebeh.2014.03.014 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S152550501400095X |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200903 | ||
| 993 | |a Article | ||
| 994 | |a 2014 | ||
| 998 | |g 12459347X |a Schubert-Bast, Susanne |m 12459347X:Schubert-Bast, Susanne |d 910000 |d 910500 |e 910000PS12459347X |e 910500PS12459347X |k 0/910000/ |k 1/910000/910500/ |p 2 | ||
| 998 | |g 134251229 |a Strzelczyk, Adam |m 134251229:Strzelczyk, Adam |p 1 |x j | ||
| 999 | |a KXP-PPN1728845440 |e 3746328802 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Strzelczyk","given":"Adam","display":"Strzelczyk, Adam","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Schubert-Bast, Susanne","role":"aut","family":"Schubert-Bast","given":"Susanne"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Reese, Jens P.","given":"Jens P.","family":"Reese"},{"display":"Rosenow, Felix","roleDisplay":"VerfasserIn","role":"aut","family":"Rosenow","given":"Felix"},{"role":"aut","display":"Stephani, Ulrich","roleDisplay":"VerfasserIn","given":"Ulrich","family":"Stephani"},{"role":"aut","display":"Boor, Rainer","roleDisplay":"VerfasserIn","given":"Rainer","family":"Boor"}],"title":[{"title":"Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam","title_sort":"Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 03.09.2020"],"recId":"1728845440","language":["eng"],"name":{"displayForm":["Adam Strzelczyk, Susanne Schubert-Bast, Jens P. Reese, Felix Rosenow, Ulrich Stephani, Rainer Boor"]},"origin":[{"dateIssuedDisp":"13 April 2014","dateIssuedKey":"2014"}],"id":{"doi":["10.1016/j.yebeh.2014.03.014"],"eki":["1728845440"]},"physDesc":[{"extent":"6 S."}],"relHost":[{"title":[{"title":"Epilepsy & behavior","title_sort":"Epilepsy & behavior"}],"pubHistory":["1.2000 -"],"part":{"pages":"86-91","year":"2014","extent":"6","text":"34(2014), Seite 86-91","volume":"34"},"titleAlt":[{"title":"Epilepsy and behavior"}],"disp":"Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazamEpilepsy & behavior","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 26.04.07"],"recId":"320590313","language":["eng"],"origin":[{"dateIssuedKey":"2000","publisher":"Elsevier ; Academic Press","dateIssuedDisp":"2000-","publisherPlace":"New York, NY [u.a.] ; Orlando, Fla."}],"id":{"issn":["1525-5069"],"zdb":["2018844-4"],"eki":["320590313"]},"physDesc":[{"extent":"Online-Ressource"}]}]} | ||
| SRT | |a STRZELCZYKEVALUATION1320 | ||